We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Biomarkers and the Risk of Preeclampsia.
- Authors
Emeruwa, Ukachi N.; Gyamfi-Bannerman, Cynthia; Laurent, Louise C.
- Abstract
A total of 968 participants were assessed to be at low risk of preterm preeclampsia based on an sFlt-1:PlGF ratio of 38 or less and were randomized in a 1:1 ratio to aspirin discontinuation between 24 and 28 weeks of gestation or aspirin continuation until 36 weeks' gestation. While the benefit of low-dose aspirin in preeclampsia prevention is well-established, the most effective daily dose for prevention of preeclampsia remains unknown. Editorial Over the past few decades, while the global incidence of preeclampsia has risen, the number of maternal and perinatal deaths due to hypertensive disorders of pregnancy has declined.[1] In 2011, international agencies, including the World Health Organization and the UK's National Institute for Health and Care Excellence, issued recommendations for daily low-dose aspirin to reduce the incidence of preeclampsia based on maternal demographics and medical history (collectively termed I maternal factors i ).[2] By 2013, similar recommendations were adopted in the US based on guidance from the US Preventive Services Task Force (USPSTF), American College of Obstetricians and Gynecologists, and Society for Maternal-Fetal Medicine.
- Subjects
UTERINE artery; PREECLAMPSIA; HIGH-risk pregnancy; ECLAMPSIA; PLACENTAL growth factor; HYPERTENSION in pregnancy; PREGNANCY complications
- Publication
JAMA: Journal of the American Medical Association, 2023, Vol 329, Issue 7, p539
- ISSN
0098-7484
- Publication type
Article
- DOI
10.1001/jama.2022.24906